ISNTD d3 2014

[May 15, 2014]
Drug Discovery & Development
London, UK

ISNTD d3 brought together experts from within drug discovery and clinical trials to drive the debate and foster new partnerships & alliances leading to tangible outcomes in terms of new therapies to combat these diseases.

ISNTD d3 aimed to accelerate the networking required for the development & distribution of new or improved drugs, vaccines, microbicides and diagnostics against the NTDs by bringing focus onto the phase II and III clinical trials taking place or set to take place potentially in affected countries.

DNDi staff participated in the following three sessions:

Session 2: Open Source
Dr. Charles Mowbray, Head of Drug Discovery, DNDi

Session 3: Clinical Trials
Dr. Nathalie Strub Wourgaft
, Medical Director, DNDi

Session 4: Funding Challenges

Jean-François Alesandrini, Fundraising & Advocacy Director, DNDi

Download programme

More information: ISNTD d3 website